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Abstract
Background: The purpose of this study was to estimate both cross-sectional sibling recurrence
risk ratio (λs) and lifetime λs for the metabolic syndrome and its individual components over time
among sibships in the prospectively followed-up cohorts provided by the Genetic Analysis
Workshop 13. Five measures included in the operational criteria of the metabolic syndrome by the
Adult Treatment Panel III were examined. A method for estimating sibling recurrence risk with
correction for complete ascertainment was used to estimate the numerator, and the prevalence in
the whole cohort was used as the denominator of λs.
Results: Considerable variability in the λs was found in terms of different time-points for the cross-
sectional definition, the times of fulfilling the criterion for lifetime definition, and different
components. Obesity and hyperglycemia had the highest cross-sectional λs of the five components.
Both components also had the largest slopes in the linear trend of the lifetime λs. However, the
magnitudes of the lifetime λs were similar to that of the mean cross-sectional λs, which were <2.
The results of nonparametric linkage analysis showed only suggestive evidence of linkage between
one marker and lifetime diagnosis of low high-density lipoprotein cholesterol and metabolic
syndrome, respectively.
Conclusion: The λs of the metabolic syndrome and its components varies substantially across
time, and the λs of lifetime diagnosis was not necessarily larger than that of a cross-sectional
diagnosis. The magnitude of λs does not predict well the maximum LOD score of linkage analysis.
Background
The metabolic syndrome is a clustering of diabetic and
cardiovascular risk factors, including obesity, hypertriglyc-
eridemia, low high-density lipoprotein (HDL) choles-
terol, hypertension, and glucose intolerance [1]. It
predicts both diabetes and cardiovascular diseases, and
indicates the existence of a common underlying mecha-
nism linking these two disorders. A recent study of twins
found that the concordance rates for glucose concentra-
tion, overall obesity, and HDL-cholesterol were signifi-
cantly higher among monozygotic twins than dizygotic
twins [2]. However, the heritability estimates for waist-to-
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hip ratio, fasting insulin, and triglycerides were found to
be low. Another study employing factor analysis of the
change in the features of the metabolic syndrome over
time revealed that change in overall obesity, as measured
by the body mass index (BMI), is central to all derived fac-
tors [3]. These findings indicate that the components of
the metabolic syndrome may have different contributions
from genes and environment, and certain component
may be central to the whole syndrome.
In assessing the familial aggregation of a disease or physi-
ological trait, the sibling recurrence risk ratio, λs, is a com-
monly used index [4]. Under a multilocus multiplicative
model, λs is proportional to the power of an affected-rela-
tive-pair genetic linkage analysis [5]. Recent studies have
revealed that λs is influenced by many factors, including
the ascertainment process and overreporting [6], as well as
allele frequency and mode of inheritance [7]. Thus, λs by
itself does not provide a reliable parameter for estimating
the statistical power of a proposed linkage study. Never-
theless, within a range of low magnitudes of genetic effect,
which probably is true for many susceptibility genes of
complex diseases, the relationship between λs and geno-
type relative risk is relatively predictable regardless of
underlying genetic models [7]. Furthermore, there are
methods to estimate λs with correction for ascertainment
[8]. Therefore, an accurate estimate of λs can serve as an
initial assessment of the genetic effect conferred to a trait
under study.
So far λs has been estimated exclusively on the basis of
cross-sectional assessment of phenotypes. When a disease
has a variable age at onset and the phenotype is repeatedly
measured, it is not known whether the λs is stable over
time. In this study, we estimated both cross-sectional λs
and lifetime λs for the metabolic syndrome and its indi-
vidual components over time among sibships in a pro-
spectively followed-up cohort. We hypothesized that a
component with a higher λs is more likely to be the central
genetic contribution to the syndrome. The distributions of
various definitions of λs over time for the metabolic syn-
drome and its individual components were compared. In
addition, genome-wide scans were performed for both
cross-sectional and lifetime phenotype definitions for the
metabolic syndrome and its individual components.
Methods
Subjects
Participants were from Cohort 1 and Cohort 2 of the
Framingham Heart Study data set provided by the Genetic
Analysis Workshop 13 (GAW13). In Cohort 1, 1231 indi-
viduals (583 males and 630 females) with a mean base-
line age of 41.5 years (ranging from 29.0 to 62.0) were
included. Cohort 2 included 1672 individuals (826 males
and 846 females) with a mean baseline age of 32.7 years
(ranging from 5.0 to 64.0). Some participants in the two
cohorts were from the same pedigree, and in total 330
pedigrees were identified. Among these pedigrees, 1702
individuals were further genotyped for genomic scanning.
Measures
In this study, we considered five measures that are
included in the operational criteria for the metabolic syn-
drome as defined by the Adult Treatment Panel III (ATP
III) [9]. Because the data on waist circumference, which
measures abdominal obesity, were not provided in the
Framingham Heart Study data set, we instead employed
overall obesity as measured by a BMI > 30 kg/m2. The cut-
off points of hypertension in the Framingham Heart Study
data set were slightly more stringent than those recom-
mended in the ATP III criteria (≥ 130 / ≥ 85 mm Hg). The
specific criteria adopted in this study were as follows: 1)
Blood pressure: systolic blood pressure (SBP) ≥ 140 mm
Hg or diastolic blood pressure (DBP) ≥ 90 mm Hg, or
under anti-hypertension treatment; 2) Obesity: BMI > 30
kg/m2; 3) Fasting glucose: ≥ 110 mg/dl; 4) Triglycerides: ≥
150 mg/dl; and 5) HDL cholesterol: < 40 mg/dl (men) or
< 50 mg/dl (women). The diagnosis of the metabolic syn-
drome was made when three or more of the criteria were
met. Phenotypic data provided in the GAW13 included
those for the first 40 years of follow-up in the Cohort 1
(Exams 1 through 21) and those of the first 20 years of fol-
low-up in the Cohort 2 (Exams 1 through 5).
Statistical analysis
Sibling recurrence risk ratio (λs) is defined as sibling recur-
rence risk (Ks) divided by the population prevalence (Kp).
Since the original pedigrees were not ascertained via any
particular phenotype considered in the present study, the
determination of proband status is problematic. Under
this circumstance, we considered every diseased individ-
ual as a proband and employed the method for estimating
sibling recurrence risk (Ks) when proband status is
unknown as proposed by Olson and Cordell [8]:
where ns(a) is the number of sibships of size s with a affect-
eds. This estimator of Ks has been shown to be unbiased
and consistent when the ascertainment is complete [8],
which is the case for this study. The denominator of λs, the
population prevalence, was estimated from the whole
cohort. Since the age range of Cohort 2 was wide, we lim-
ited the analysis of Cohort 2 to those aged between 30 and
60 years old.
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We estimated cross-sectional λs for each exam and then
calculated the standard deviation and the range of the esti-
mated λs across the exams. Furthermore, we defined a life-
time λs,e≥t as the condition that an individual had ever had
the episode fulfilling the criterion at least t times during the
whole study period. As t increases, the person is supposed
to have higher probability of carry the genetic susceptibil-
ity of the phenotype. In assessing the lifetime λs for the
metabolic syndrome, any particular criterion was consid-
ered fulfilled if the individual had ever any measures
above the threshold during lifetime, and a positive diag-
nosis was given if three or more criteria were met in this
way.
For each component and the metabolic syndrome per se,
we then performed nonparametric linkage analyses for
the pedigrees using GENEHUNTER [10] with the option
of all affected pairs in a pedigree. Four kinds of phenotype
definition were employed: cross-sectional diagnosis, life-
time diagnosis with episode ≥ 1, lifetime diagnosis with
episode ≥ 2, and lifetime diagnosis with episode ≥ 3. For
the cross-sectional diagnosis, we chose the data from
Exam 11 for Cohort 1 members and Exam 1 for Cohort 2
members because the two test points were chronologically
close to each other. However, for Cohort 1 members, the
height was from Exam 10 and the glucose level was from
Exam 12 because no relevant data were available in Exam
11. The genotyping was done in 1702 individuals using
399 microsatellite markers on the 22 autosomal chromo-
somes. The allele frequencies of the markers and the sex-
specific genetic maps were provided by the GAW13. The
number of affected individuals for the four phenotype
definitions (cross-sectional, lifetime ≥ 1, lifetime ≥ 2, life-
time  ≥ 3) varied as follows: (255, 898, 713, 545) for
hypertension, (185, 512, 384, 304) for obesity, (341, 597,
314, 182) for hyperglycemia, (228, 656, 348, 208) for
hypertriglyceridemia, (522, 1046, 700, 482) for low HDL
cholesterol, and (147, 699) for the metabolic syndrome
(only cross-sectional and lifetime ≥ 1 were applicable).
Results
For the cross-sectional λs in both cohorts, there were sub-
stantial variations across exams for hyperglycemia and
obesity, while the values of λs for hypertension and low
HDL were relatively stable (Figure 1). Meanwhile, an
increasing trend with the number of episode was noted
for the lifetime λs except those of hypertension and low
HDL in Cohort 1. Comparing the mean value of cross-sec-
tional λs over time in Cohort 1, obesity had the highest
mean, while the remaining components had a mean λs
less than 1.5 (Table 1). In terms of the SD of the cross-sec-
tional λs, there were considerable differences among dif-
ferent components, ranging from 0.14 (hypertension) to
0.68 (hyperglycemia). For the lifetime λs in Cohort 1, a
linear trend of increase with the number of episode was
noted for obesity and hyperglycemia. The lifetime λs of
low HDL had a sudden drop at λs,e≥3, probably due to
small number of participants meeting the threshold,
whereas the three lifetime λs of hypertension were very
similar to one another.
For the Cohort 2, the highest mean of cross-sectional λs for
individual components of the metabolic syndrome was
that for hyperglycemia, followed by obesity (Table 1). For
the remaining three components, the mean λs was below
1.5. A linear trend of increase with the number of episode
among the three types of lifetime λs could be seen in all
components, with hyperglycemia having the largest
increase. However, similar to the pattern observed in
Cohort 1, the lifetime definition of λs led to a decrease
over the cross-sectional definition in most cases. The λsof
the metabolic syndrome, regardless of cross-sectional or
lifetime, seemed to fall between those of its components
in both Cohort 1 and Cohort 2.
The markers that had a maximum LOD score ≥ 1.5 in the
genome-wide scan is displayed in Table 2. For the cross-
sectional diagnosis, only hypertriglyceridemia and low
HDL cholesterol had such markers, while for the lifetime
diagnosis each component and the metabolic syndrome
had markers with LOD score ≥ 1.5, with the lifetime diag-
nosis with episode ≥ 1 having the most such markers. The
same marker did not consistently appear in all phenotype
definitions. Some markers appeared in more than one
trait under the same type of phenotype definition, such as
C12g3 in obesity, low HDL, and the metabolic syndrome,
and C17g2 in hypertension and hypertriglyceridemia.
Overall, suggestive evidence of linkage (LOD ≥ 2.2) was
found only for the lifetime diagnosis with episode ≥ 1 of
low HDL and the metabolic syndrome.
Discussion
The results of the λs analyses demonstrated that there is a
modest to moderate magnitude of familial aggregation for
the metabolic syndrome and its components. However,
considerable variability in λs was found in terms of differ-
ent time-points for the cross-sectional definition, the
times of fulfilling the criterion for the lifetime definition,
and different components of the metabolic syndrome.
The variability of cross-sectional λs over time is quite dif-
ferent among the components of the metabolic syn-
drome, with hypertension having the smallest SD and
hyperglycemia having the largest SD in both Cohort 1 and
Cohort 2. This finding highlights the instability of a single
time-point estimate of λs for certain phenotypic measures.
Several reasons may account for this. First, the distribu-
tion of the original phenotypic measures was skewed for
the majority of components and was not bimodal in
shape. The arbitrary threshold used by the ATP III criteriaBMC Genetics 2003, 4 http://www.biomedcentral.com/1471-2156/4/s1/S33
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The trends of sibling recurrence risk ratios λs of individual components of the metabolic syndrome and the syndrome per se in  Cohort 1 (A) and Cohort 2 (B) Figure 1
The trends of sibling recurrence risk ratios λs of individual components of the metabolic syndrome and the syndrome per se in 
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Table 1: The sibling recurrence risk ratios (λs) of individual components of the metabolic syndrome and the syndrome per se in Cohort 
1 and Cohort 2.
Cross-sectional λs Lifetime λs
Variable n Mean (SD) Range λs,e≥1 λs,e≥2 λs,e≥3
Cohort 1
Hypertension 21 1.22 (0.14) 1.11–1.72 1.03 1.04 1.07
Obesity (high 
BMI)
12 1.91 (0.48) 1.37–2.95 1.32 1.46 1.86
Hyperglycemia 14 1.39 (0.68) 0.77–3.57 1.14 1.28 1.47
Hypertriglyceri
demia
1A 1.32 - 1.28 - -
Low HDL 
cholesterol
3 1.34 (0.23) 1.07–1.52 1.21 1.50 0.34
Metabolic 
syndrome
-- 1 . 2 1 - -
Cohort 2B
Hypertension 5 1.34 (0.10) 1.25–1.48 1.20 1.35 1.38
Obesity (high 
BMI)
5 1.60 (0.21) 1.39–1.89 1.40 1.54 1.56
Hyperglycemia 5 1.81 (0.57) 1.27–2.77 1.18 1.32 2.22
Hypertriglyceri
demia
5 1.32 (0.19) 1.09–1.56 1.20 1.41 1.43
Low HDL 
cholesterol
5 1.30 (0.10) 1.15–1.42 1.10 1.25 1.42
Metabolic 
syndrome
5 1.45 (0.30) 0.95–1.74 1.25 - -
AThe other two measures of triglycerides led to too few subjects for the estimation. BLimited to subjects aged 30–60 years.
Table 2: Results of nonparametric linkage analysis of genome-wide scanning with LOD score ≥ 1.5 (if two or more adjacent markers, 
only the one with the highest score listed).
Trait Cross-Sectional Diagnosis 
Marker (LOD)
Lifetime Diagnosis
Episode ≥ 1 Marker (LOD) Episode ≥ 2 Marker (LOD) Episode ≥ 3 Marker (LOD)
Hypertension - C1g32 (1.6) C1g32 (1.6) C1g32 (1.6)
C17g2 (2.1) C9g11 (1.7) C9g11 (1.7)
C22g1 (1.5) C22g1 (1.5) C22g1 (1.5)
Obesity (high BMI) - - C8g10 (1.5) C8g10 (1.5)
-C 1 2 g 3  ( 1 . 5 )- -
-C 1 9 g 1 1  ( 1 . 5 )- -
Hyperglycemia - C3g26 (1.5) - -
-C 8 g 1 0  ( 1 . 5 )- -
-C 1 0 g 8  ( 1 . 5 )- -
Hypertriglyceridemia - C6g8 (1.8) - -
C10g12 (1.5) C10g12 (1.6) - -
- C13g9 (1.5) C13g9 (1.5) C13g9 (1.5)
-C 1 7 g 2  ( 1 . 9 )- -
C22g7 (1.5) C22g7 (1.5) C22g7 (1.5) -
Low HDL cholesterol C9g7 (2.0) - -
C10g11 (1.5) - C10g12 (1.8) C10g12 (1.6)
-C 1 2 g 3  ( 1 . 8 )- -
- - C13g8 (1.5) C13g8 (1.5)
-C 1 6 g 3  ( 1 . 9 )- -Publish with BioMed Central    and   every 
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might lead to fluctuation over time in prevalence and the
subsequent estimates of λs. Second, the number of sib-
lings eligible for Ks estimation became very small when
the prevalence was low, e.g., around 30 for hyperglycemia
in Cohort 1.
With our definitions of lifetime λs,e≥t, it is expected that the
more times a person meets the criteria, the higher proba-
bility that the individual carries the susceptibility geno-
type(s). Indeed, a linear trend in lifetime λs was noted in
the majority of the components of the metabolic syn-
drome, especially hyperglycemia. However, the value of
the lifetime λs,e≥3 was not necessarily greater than the
mean cross-sectional λs of its counterpart, with some even
lower than the latter (e.g., obesity). This may further call
into question the use of cross-sectional λs.
Comparing the one-time λs of the components of the met-
abolic syndrome, obesity and hyperglycemia stand out as
the highest components for both Cohort 1 and Cohort 2.
Both components also had the largest slope in the linear
trend of the lifetime λs. Thus, both obesity and hyperglyc-
emia might be the central components of the metabolic
syndrome in terms of familiality. This is consistent with
the findings in twin analysis [2] and longitudinal factor
analysis [3] of the metabolic syndrome.
Despite the evidence supporting the familial aggregation
of the metabolic syndrome and its components, the mod-
est to moderate magnitude of the λs (its mean not greater
than 2) found in this study implies that very large samples
of affected relative pairs are needed for the detection of
definitive genetic linkage [5,7]. This indeed is the result
for our nonparametric linkage analysis of the metabolic
syndrome and its components, respectively. Although it
appeared that there was no relation between the magni-
tude of λs and the number of markers with LOD score ≥
1.5, the widely varying number of affected individuals for
each component might account in part for this. Neverthe-
less, the repeated appearances of some markers across dif-
ferent traits indicate that these traits might indeed share
certain common genetic susceptibility.
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